F

Fennec Pharmaceuticals Inc
NASDAQ:FENC

Watchlist Manager
Fennec Pharmaceuticals Inc
NASDAQ:FENC
Watchlist
Price: 8.67 USD -2.91% Market Closed
Market Cap: 241.3m USD

EV/EBIT
Enterprise Value to EBIT

-25
Current
-10.2
Median
6.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-25
=
Enterprise Value
241.9m USD
/
EBIT
-9.7m USD
EBIT Growth EV/EBIT to Growth
US
F
Fennec Pharmaceuticals Inc
NASDAQ:FENC
Average EV/EBIT: 18.4
Negative Multiple: -25
135%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 861.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.7 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.8
17%
1.2
AU
CSL Ltd
ASX:CSL
17.6
14%
1.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.4
12%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -323.2 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.9 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
88.3
2-Years Forward
EV/EBIT
11.6
3-Years Forward
EV/EBIT
7.2